Retinal pigment epithelial tear after intravitreal bevacizumab injection

Am J Ophthalmol. 2006 Dec;142(6):1070-2. doi: 10.1016/j.ajo.2006.07.037. Epub 2006 Sep 12.

Abstract

Purpose: To report two cases of a retinal pigment epithelial (RPE) tear after intravitreal bevacizumab injection for exudative age-related macular degeneration (AMD).

Design: Observational case series.

Methods: Two patients presented with occult choroidal neovascularization secondary to AMD. Both patients received intravitreal bevacizumab injections.

Results: The first patient developed a RPE tear shortly after a third intravitreal bevacizumab injection. The second patient developed a RPE tear 10 days after a second intravitreal bevacizumab injection.

Conclusions: Although RPE tears may occur spontaneously as part of the natural history of exudative AMD, patients may develop visually devastating RPE tears after repeat intravitreal bevacizumab injection. Further studies are needed to determine the incidence of RPE tears after intravitreal bevacizumab injections.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Choroidal Neovascularization / drug therapy
  • Choroidal Neovascularization / etiology
  • Exudates and Transudates
  • Female
  • Fluorescein Angiography
  • Humans
  • Injections
  • Macular Degeneration / complications
  • Macular Degeneration / drug therapy
  • Pigment Epithelium of Eye / drug effects*
  • Pigment Epithelium of Eye / pathology
  • Retinal Perforations / chemically induced*
  • Retinal Perforations / diagnosis
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab